Plandai Biotechnology Appoints Paritz & Company as New Auditor

Performing Two Year Audit for Plandaí to Become Current and SEC Compliant

LONDON, UNITED KINGDOM , March 27, 2018 (GLOBE NEWSWIRE) -- Plandaí Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, today announced the appointment of Paritz & Company as its new auditor.

Paritz & Company will be performing a two-year audit to bring Plandaí current with its financials as the Company seeks to become SEC compliant.

Paritz & Company, P. A. is a mid-size regional accounting and consulting firm servicing clients in the New York tri-state area and operations of multi-national companies. Its main office is located in Hackensack, New Jersey and they are licensed Certified Public Accountants in several States and registered with the PCAOB. The partners and principals of the Firm have experience in auditing and taxation with domestic and international firms.

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. (OTC Markets: PLPL) develops highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company's products include poultry, dietary supplements, diabetes and cannabis. Plandai Biotechnology is headquartered in London, United Kingdom. For more information, please visit: http://www.plandaibiotech.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company's filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Contact Information: Hayden IR (917) 658-7878 hart@haydenir.com Marlin Molinaro Marmel Communications, LLC (828) 669-0616 mmolinarofc@aol.com

Source:Plandai Biotechnology, Inc.